The core utility of this agent is the management of the physical and conscious state of veterinary patients, and it is applied in addressing heightened systemic burden. It is indicated for the induction and maintenance of general anesthesia in dogs and cats.

---

Inducing and Maintaining Profound Immobility and Unconsciousness

This medication is used to address the domains of consciousness and sensation. It is applied to help facilitate a necessary, controlled loss of patient awareness and responsiveness. It is commonly applied in clinical settings that involve major surgical procedures or extensive diagnostic imaging, and is relevant in clinical settings that involve acute or unstable symptom patterns that require complete immobility. The medication helps to provide profound muscle relaxation and immobility. This provides support that helps ease the overall symptom burden.

Minimizing Risk in High-Risk and Sensitive Patients

Alfaxan supports the management of anesthetic needs in high-risk patients, including those with compromised cardiorespiratory status or underlying health issues. This use is also relevant in specialized contexts, such as during Caesarean sections (C-sections). This use is considered relevant for easing the overall physiological strain on vulnerable patients.

---

Quick Fact: Relevant for Suppression of Motor Activity

Regulatory References

1. FDA Freedom of Information Summary for Alfaxan

Official Eligibility and Contraindications

Regulatory documents define strict population eligibility for Alfaxan (alfaxalone) based on species, age, and health status.

Eligibility Status	Population Criteria
Allowed Use	Dogs, Cats, and indexed non-food-producing minor species (e.g., specific reptiles, pet birds, captive rodents).
Contraindicated Use	Animals with known hypersensitivity to alfaxalone or its components. Any patient for whom general anesthesia is clinically contraindicated. Minor species intended for human consumption or food production.
Conditional Use/Caution	Aged animals require additional monitoring. Patients with severe hepatic impairment or renal insufficiency may require a reduction in administration rate or dose. Caution is also advised for hypovolaemic or debilitated animals.

Age and Reproductive Status

The label specifies minimum age thresholds, which may vary by region. Safety has been demonstrated in puppies at least 10 weeks old and kittens at least 4 weeks old (US label), but use is generally not established in younger age groups. Use during general pregnancy and lactation is not established, but the drug is supported for the induction of anesthesia prior to Caesarean section in dogs.

Interactions with other medicines and products

This section details the officially documented interaction profile of Alfaxan, as established by governmental regulatory agencies.

Interaction Category	Officially Documented Interaction Entities
Pharmacodynamic Interactions	Central Nervous System (CNS) Depressants (Potentiation)
Administration Restrictions	Other therapeutic agents (Prohibited physical mixing)
Population Clearance Note	Chronic liver disease (Slower excretion rate)

---

Interaction Scope and Constraints

The medicine is officially recognized to interact primarily through pharmacodynamic potentiation with other CNS depressants, including classes such as opioids, phenothiazines, benzodiazepines, and alpha-2-adrenoceptor agonists. Co-administration with these agents will officially influence patient response. For instance, preanesthetic agents are documented to reduce the Alfaxalone induction dose (a dose-sparing effect), while alpha2-agonists may markedly increase the duration of anaesthesia.

A critical restriction is the requirement that Alfaxan must not be mixed with other therapeutic agents prior to administration due to physical and chemical incompatibility. No specific drug-drug interactions related to CYP enzymes, food, alcohol, or supplements are documented in the official regulatory prescribing information.

Population-Specific Notes

The profile also includes a population-specific interaction caution: in patients with chronic liver disease, Alfaxalone may be excreted at a slower rate than in healthy patients, an outcome related to its clearance via glucuronic acid conjugation.

Regulatory Structure Summary

Regulatory documents define the product's interaction structure through mandatory administration protocols and expected additive CNS effects. The official profile explicitly details the effect of common preanesthetic classes resulting in a marked dose-sparing effect and addresses the slower excretion rate potentially observed in patients with compromised hepatic function.

Molecular Mechanism: Positive Modulation of GABA A Receptors

The primary function of Alfaxalone is to act as a positive allosteric modulator on GABA A receptors located in the central nervous system. This molecular action enhances the effect of the inhibitory neurotransmitter GABA, leading to a greater influx of chloride ions ( Cl^-) and subsequent hyperpolarization of the neuronal membrane. This molecular interaction initiates the cascade of central nervous system depression.

---

The Cascade: Systemic Inhibition and CNS Depression

The potentiation of GABAergic signaling translates into widespread inhibition of neuronal excitability across the central nervous system, particularly within the cortex and brainstem. This systemic depression of the key pathways regulating consciousness and arousal produces a loss of awareness and responsiveness, along with concurrent muscle relaxation due to central motor neuron suppression. The compound exhibits rapid metabolism, leading to a quick cessation of the GABA A receptor potentiation.

---

Physiological Consequence: Absence of Primary Analgesic Action

The drug's mechanism is confined to the sedative-hypnotic domain via GABA A receptors and does not directly engage the primary biological pathways for pain signaling (nociception), such as those mediated by opioid receptors or NMDA receptors. Therefore, the mechanistic profile requires co-administration with a dedicated analgesic to address pain signaling. The GABA A system's rapid response characteristics contribute to the drug's rapid onset and offset of effect.

Administration Route and Form

Alfaxan is supplied as a 10 mg/mL aqueous solution for injection and is approved exclusively for intravenous (IV) administration. This is the only official route permitted for its use as a general anesthetic. The solution must be handled according to specific administrative constraints; it is explicitly documented that Alfaxan must not be mixed with any other therapeutic agents prior to injection.

---

Dosing Regimens and Titration

The initial process, known as induction, requires the dose to be carefully titrated to effect by administering the IV injection slowly, typically over a period of approximately 60 seconds. The exact dosage required is critically dependent on the patient's premedication status; the use of preanesthetic agents results in a significant dose-sparing effect, thereby reducing the total volume of alfaxalone needed for induction. Anesthesia maintenance is achieved using either small, intermittent IV boluses or a Constant Rate Infusion (CRI). For continuous maintenance, the intermittent boluses are generally administered every 7 to 10 minutes, or a CRI regimen is initiated, adhering to specified ranges. The short-acting nature of the drug makes repeated administration necessary for sustained unconsciousness throughout the procedure. Any remaining contents in a multi-dose vial must be discarded after its specified shelf-life from first puncture.

Research evidence / Overview of studies for Alfaxan

This section provides an overview of the official research, including randomized controlled trials and regulatory evaluations, that research examined Alfaxan's utility as a general anesthetic in authorized species, focusing on the acute effects.

---

Evidence for Anesthetic Induction and Maintenance

The core evidence regarding Alfaxan comes primarily from Randomized Controlled Trials (RCTs) and controlled pharmacological studies. These research programs was studied for the characteristics of the medicine as a short-term anesthetic for surgical and diagnostic procedures in dogs and cats.

Studies research examined the quality of anesthetic onset, including the time required to achieve loss of consciousness and the overall smoothness of the induction phase. Trials also monitored the stability and depth of the anesthetized state during the procedure, focusing on the achievement of muscle relaxation. The studies also evaluated the sustained anesthetized state observed during the use of the agent. When research described patterns related to recovery, it focused on how quickly subjects awoke, including the time taken to regain consciousness and return to a normal posture. These findings describe group patterns and contribute to the broader evidence landscape.

---

Research in Specialized Anesthetic Contexts

Specific clinical research studies explored the use of Alfaxan in specialized or high-risk contexts. For instance, multicenter, prospective clinical trials was evaluated in female dogs undergoing Caesarean sections (C-sections).

In these specialized studies, researchers monitored the anesthetic quality in the mother and simultaneously observed in the viability of the newborn puppies. The outcomes related to the puppies was observed in some studies using assessment tools like modified Apgar scoring, and short-term survival rates was monitored. Findings describe patterns observed in the studies that compared the outcomes of Alfaxan induction to standard alternative protocols in this setting. Research highlights changes measured during the study period for both the mother and the neonates.

---

Study Focus on Physiological Systems

A major component of the research studies explored the effects observed on critical bodily functions during anesthesia. This research was studied for temporary physiological imbalance that may occur when anesthetic agents are administered.

Clinical trials systematically research examined key physiological strain or stress parameters, including heart rate, arterial blood pressure, respiratory rate, and oxygen levels. These measurements data show patterns related to the stability of the subject's condition during the phases of induction and maintenance. While studies examined short-term changes in these variables, often describing transient fluctuations upon induction, the evidence contributes to understanding the agent's overall profile in a controlled setting.

---

Long-Term Data and Evidence Gaps

The evidence base for Alfaxan is concentrated on the perianesthetic period—the time immediately surrounding the procedure—reflecting its authorized use as an acute, short-term agent.

Follow-up durations were limited in the main clinical trials. As a result, long-term effects are not fully established, and there is limited information for long-term outcomes or effects extending beyond the immediate recovery phase. The available research reflects the populations studied, primarily healthy and compromised dogs and cats. Data for certain groups remain insufficient, and the research lacks data for fully characterizing the use of Alfaxan in certain complex clinical scenarios or non-authorized species. The evidence highlights what is known—and what is still uncertain—about this medication.

Key Studies & References

1. FDA Freedom of Information Summary - NADA 141-283 (Alfaxan®)

Common questions about Alfaxan (FAQ)

Q: Is Alfaxan a controlled substance, and what does that classification mean?

A: According to official regulatory documents, Alfaxan contains alfaxalone, which is classified as a Schedule IV controlled substance. This classification indicates that the drug has an accepted medical use and a low potential for abuse or dependence. This designation is common for drugs that affect the central nervous system, such as sedatives.

Q: Does the current Alfaxan formulation cause allergic reactions or histamine release?

A: The current Alfaxan product was developed using a special solubilizing agent called cyclodextrin, which replaced an older solvent associated with certain safety concerns. Official data describes the benefit-risk profile as favorable when the drug is used as directed. Product information states that the medicine is contraindicated if an animal has a known hypersensitivity to alfaxalone or its components.

Q: Does Alfaxan have a cumulative effect if repeated doses are given?

A: Studies and official information indicate that alfaxalone is rapidly cleared and metabolized by the body. Research on the drug’s short half-life suggests that the risk of significant accumulation in the patient’s system is low, which is important for maintaining control during an anesthetic procedure.

Q: Is the recovery period from Alfaxan different compared to other injectable anesthetics like propofol?

A: Research supporting the drug’s approval highlights that Alfaxan typically provides a rapid and smooth recovery from anesthesia. This characteristic is part of its pharmacological class as a short-acting agent, allowing animals to wake up quickly once administration is stopped.

Q: What is the difference between Alfaxan and the active ingredient alfaxalone?

A: Alfaxalone is the single active drug substance, meaning it is the actual ingredient that causes the anesthetic effect. Alfaxan is the commercial trade or brand name of the product that contains alfaxalone as a solution for injection.

Q: Why was the original version of this drug formulation (Saffan) taken off the market?

A: The current formulation of Alfaxan was specifically developed to use a solubilizing agent called cyclodextrin. This specific chemical change was implemented to address safety concerns, such as the potential for histamine release, that were associated with the older solvent used in certain previous alfaxalone products.

Q: Is Alfaxan a hormone or does it have steroid effects on the body?

A: Alfaxalone is chemically classified as a neuroactive steroid, meaning it is structurally related to steroids but acts on the brain. Despite its chemical structure, official information confirms it is not a hormone and does not have glucocorticoid or mineralocorticoid activity (hormone effects) in the body. Its effect is purely anesthetic via the GABA A receptor.

Q: Is Alfaxan safe for use in certain dog breeds like Sighthounds (e.g., Greyhounds)?

A: Research supporting the drug’s use specifically studied the administration of Alfaxan in Greyhound dogs, which are sometimes sensitive to other anesthetic agents. The research concluded the agent can be used to provide short-term anesthesia in this breed.

Q: Does Alfaxan affect the pressure inside the eyes (intraocular pressure)?

A: Official research has shown that Alfaxan may cause a temporary increase in intraocular pressure (IOP) in animals upon induction. This temporary physiological change is monitored during procedures, particularly those involving the eyes.

Q: What is the difference between Alfaxan Multidose and Alfaxan Multidose IDX?

A: The products are chemically identical. Alfaxan Multidose is approved for use in dogs and cats, which are considered major species. Alfaxan Multidose IDX is approved under a different regulatory pathway specifically for a range of non-food-producing minor species.

Q: Are there special precautions for people handling Alfaxan due to the risk of accidental injection?

A: Alfaxan is not for human use. Regulatory information states that caution must be exercised by the handler to avoid accidental self-injection. If this exposure occurs, it is considered a medical emergency that requires immediate medical attention, as it can lead to cardiorespiratory depression.

Alfaxan must be stored at controlled room temperature, generally defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C [1]. The product must not freeze [2].

To ensure product stability and protection, it must be stored in the original outer carton to protect the contents from light [3]. The container should be kept tightly closed and must be stored out of the sight and reach of children [4, 5].

Stability and Disposal

For multi-dose formulations containing a preservative, the product is stable for up to 56 days after the vial is first punctured, after which any remaining solution must be discarded [6]. For preservative-free formulations, any unused solution must be immediately discarded upon withdrawal of the required dose [7].

Disposal of unused or expired product and related waste materials, including used needles, must strictly follow all local regulatory requirements [8]. The medicine should not be disposed of in household waste or via wastewater [2].